Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.34 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205581 | 0.80 | APP (0.55) | APP | |
| Phosphoric Acid SCHEMBL1513833 | 0.78 | RAB9A (0.42) | CYP1A2 | |
| SCHEMBL1104937 | 0.75 | APP (0.55) | APPCYP1A2HDAC6SLC16A3 | |
| SCHEMBL1513840 | 0.75 | MEN1 (0.43) | CYP1A2HDAC6 | |
| SCHEMBL13428176 | 0.75 | APP (0.68) | APPSTSCYP1A2INPPL1INPP5A | |
| SCHEMBL1104920 | 0.71 | APP (0.48) | APPSLC16A3 | |
| SCHEMBL10674132 | 0.71 | GRIN1 (0.42) | HDAC6 | |
| SCHEMBL9295847 | 0.71 | GAA (0.46) | CYP1A2 | |
| SCHEMBL10264705 | 0.67 | APP (0.44) | APP | |
| SCHEMBL4532475 | 0.65 | SLC16A3 (0.68) | STSSLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053252-A1 | NUCLEIC ACID AMPLIFICATION AND SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053252-A1 | NUCLEIC ACID AMPLIFICATION AND SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011038241-A1 | NUCLEIC ACID AMPLIFICATION AND SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053252-A1 | NUCLEIC ACID AMPLIFICATION AND SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES | RNGTT, POLI, NT5E | APP 4203/4885STS 2356/4885CYP1A2 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.